Search Results for "bicalutamide"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for bicalutamide. Results 1 to 6 of 6 total matches.
See also: Casodex
Bicalutamide for Prostate Cancer
The Medical Letter on Drugs and Therapeutics • Jun 21, 1996 (Issue 977)
Bicalutamide for Prostate Cancer ...
Bicalutamide (Casodex - Zeneca), an oral nonsteroidal antiandrogen similar to flutamide (Eulexin - Medical Letter, 31:72, 1989), is now available in the USA for treat-ment of advanced prostate cancer. The drug is recommended by the manufacturer for use concurrently with an analog of luteinizing hormone-releasing hormone (LHRH) such as leuprolide (Lupron; Lupron Depot) or goserelin (Zoladex -Medical Letter, 32:102, 1990).
Degarelix (Firmagon) for Prostate Cancer
The Medical Letter on Drugs and Therapeutics • Oct 19, 2009 (Issue 1323)
%) also
received the antiandrogen bicalutamide. The primary
endpoint of the study was the rate ...
The FDA has approved degarelix (Firmagon - Ferring), a synthetic decapeptide gonadotropin-releasing hormone (GnRH) receptor antagonist, for rapid medical castration of men with advanced prostate cancer. Abarelix (Plenaxis), the first GnRH antagonist approved by the FDA, was withdrawn from the US market because of immediate hypersensitivity reactions.
Abarelix (Plenaxis) for Advanced Prostate Cancer
The Medical Letter on Drugs and Therapeutics • Mar 15, 2004 (Issue 1178)
473.67
Triptorelin – Trelstar Depot (Pfizer)
6
3.75 mg/28 days IM 419.60
ANTIANDROGENS
Bicalutamide ...
Abarelix (Plenaxis - Praecis Pharmaceuticals), an injectable gonadotropin-releasing hormone (GnRH) antagonist, has been approved by the FDA for treatment of advanced symptomatic prostate cancer in patients who should not take luteinizing hormone-releasing hormone (LHRH) agonists and who refuse treatment with surgical castration.
Relugolix (Orgovyx) for Advanced Prostate Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Jul 24, 2023 (Issue 1681)
generally also
receive an antiandrogen (e.g., bicalutamide) for the
first few weeks.1,2 GnRH receptor ...
The oral gonadotropin-releasing hormone (GnRH)
receptor antagonist relugolix (Orgovyx – Myovant
Sciences/Pfizer) has been approved by the FDA for
treatment of advanced prostate cancer in adults. It
is the first oral GnRH receptor antagonist to become
available in the US; degarelix (Firmagon), an injectable
GnRH receptor antagonist, has been available since
2008 for the same indication.
Med Lett Drugs Ther. 2023 Jul 24;65(1681):e121-2 doi:10.58347/tml.2023.1681e | Show Introduction Hide Introduction
Drugs of Choice for Cancer
Treatment Guidelines from The Medical Letter • Mar 01, 2003 (Issue 7)
, vinblastine, paclitaxel or etoposide;
(flutamide, bicalutamide or nilutamide) ketoconazole ± either ...
The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. In some cases, such as elderly patients or those with many co-morbid illnesses, the regimen of choice might not be suitable. For many of the cancers listed, surgery and/or radiation therapy may be the treatment of choice or may also be part of the management. Anticancer...
Drugs of Choice for Cancer Chemotherapy
The Medical Letter on Drugs and Therapeutics • Mar 31, 1995 (Issue 945)
)
agonists (leuprolide or goserelin) ± antiandrogen (flutamide, bicalutamide, or nilutamide)
Mitoxantrone ...